Taysha Gene Therapies, Inc. — Form 4
Filed July 10, 2026 · analyzed by the Insider Agent
4
▼ Likely negative
significance 44/100
What the filing says
President and Head of R&D Nagendran Sukumar (TSHA) sold 200K shares (~$1.2M) on the open market (18% of holdings). Open-market sale — often routine.
Why this rating
Open-market sale — often routine.
See more from July 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.